3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Conditions
Melanoma
14
Carcinoma, Renal Cell
10
Carcinoma, Non-Small-Cell Lung
7
Carcinoma, Transitional Cell
4
Neoplasms
3
Neoplasm Metastasis
3
Clear-cell metastatic renal cell carcinoma
3
Carcinoma, Hepatocellular
3
Thyroid Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Nasopharyngeal Carcinoma
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Kidney Neoplasms
2
Brain Neoplasms
2
Vulvar Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Urachal adenocarcinoma
1
Triple Negative Breast Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Somatostatinoma
1
Skin Neoplasms
1
Seminoma
1
Sarcoma
1
Interventions
Carboplatin
29
pembrolizumab
25
Pemetrexed
25
Specimen Handling
22
Cisplatin
20
Magnetic Resonance Spectroscopy
18
Paclitaxel
15
Gemcitabine
13
Docetaxel
12
durvalumab
9
Nivolumab
8
osimertinib
7
Taxes
7
Immunoglobulin G
7
Disulfides
7
130-nm albumin-bound paclitaxel
7
atezolizumab
6
Etoposide
6
Platinum
5
Cetuximab
5
1,2-diaminocyclohexaneplatinum II citrate
5
X-Rays
4
Ramucirumab
4
Radiotherapy
4
Radiation
4
Observation
4
Interviews as Topic
4
Biopsy
4
Albumin-Bound Paclitaxel
4
patritumab deruxtecan
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
Ipilimumab
×
30 days
×
Clear all
NCT07603856
2026-05-22
REVIVE
University of Chicago
Phase 2
Not yet recruiting
39 enrolled
NCT07394062
2026-05-18
ALCG-01
Gazi University
Recruiting
400 enrolled